# Combination therapy using siRNA nanocompelex and PD-L1 inhibitor for alcoholic liver fibrosis

> **NIH NIH R01** · UNIVERSITY OF MISSOURI KANSAS CITY · 2021 · $46,740

## Abstract

Project Summary
 The purpose of this administrative supplement application is to purchase a SpectraMax iD5 Multi-
Mode Microplate Reader with bottom luminescence read mode. The SpectraMax iD5 Multi-Mode
Microplate Reader is a five-mode reader that measures absorbance, fluorescence, luminescence, time-
resolved fluorescence (TRF), and tunable fluorescence polarization (FP) for a broad range of
applications. We currently have a 15-year-old plate reader (SpectraMax Gemini XPS), which is not
working properly. In addition, our plate reader is an old model, which cannot be used for protein binding
assay using HTRF.
 We have completed all the work in Aim 1 and most of the work in Aim 2 of the parent grant. For the
rest studies in Aims 2 and 3, we will heavily depend on the use of a multi-mode microplate reader to
frequently conduct protein binding assay, cellular uptake study, immunoassay, cell viability assay,
ELISA, BCA assay, ALT/AST assay, western blot, and cell proliferation assay. Therefore, there is an
urgent need to purchase the new SpectraMax iD5 plate reader for our research.
 The acquisition of the Multi-Mode Microplate Reader will significantly enhance our capability to
make good progress in the research. This is essential for the success of the proposed animal studies to
evaluate the stability, biodistribution, and activity of the PCBP2 siRNA nanocomplex in combination with
the anti-PD-L1 inhibitor in a rat model of liver fibrosis.

## Key facts

- **NIH application ID:** 10451030
- **Project number:** 3R01AA021510-09S2
- **Recipient organization:** UNIVERSITY OF MISSOURI KANSAS CITY
- **Principal Investigator:** Kun Cheng
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $46,740
- **Award type:** 3
- **Project period:** 2012-09-15 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10451030

## Citation

> US National Institutes of Health, RePORTER application 10451030, Combination therapy using siRNA nanocompelex and PD-L1 inhibitor for alcoholic liver fibrosis (3R01AA021510-09S2). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10451030. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*